A phase II study of biweekly carboplatin (Cb) and gemcitabine (G) with bevacizumab (B) as first-line treatment in patients with advanced, inoperable stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC).

S. Bommakanti,Timothy Larson,Arkadiusz Z. Dudek,J. Koopmeiners,Priya Kumar

A phase II study of biweekly carboplatin (Cb) and gemcitabine (G) with bevacizumab (B) as first-line treatment in patients with advanced, inoperable stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC).

2010

S. Bommakanti
Timothy Larson
Arkadiusz Z. Dudek
J. Koopmeiners
Priya Kumar

e18091 Background: Cb and G is an active platinum doublet used as first line therapy in advanced, inoperable lung cancer. The addition of B to a platinum doublet has shown improved efficacy. A comb...

Keywords:

Bevacizumab
Carboplatin
Phases of clinical research
Squamous non-small cell lung cancer
Gemcitabine
Oncology
Internal medicine
Medicine
non squamous
non-small cell lung cancer (NSCLC)
first line treatment
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations